======= PCGF5 =======
== Gene Information ==
* **Official Symbol**: PCGF5
* **Official Name**: polycomb group ring finger 5
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=84333|84333]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q86SE9|Q86SE9]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=PCGF5&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PCGF5|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/617407|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Component of a Polycomb group (PcG) multiprotein PRC1- like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility (PubMed:26151332). Within the PRC1-like complex, regulates RNF2 ubiquitin ligase activity (PubMed:26151332). Plays a redundant role with PCGF3 as part of a PRC1-like complex that mediates monoubiquitination of histone H2A 'Lys-119' on the X chromosome and is required for normal silencing of one copy of the X chromosome in XX females (By similarity). {ECO:0000250|UniProtKB:Q3UK78, ECO:0000269|PubMed:26151332}.
|zf-C3HC4|
|inactivation of X chromosome by genetic imprinting|
|X chromosome|
|histone H2A-K119 monoubiquitination|
|PRC1 complex|
|dosage compensation by inactivation of X chromosome|
|histone H2A monoubiquitination|
|regulation of gene expression by genetic imprinting|
|dosage compensation|
|genetic imprinting|
|histone H2A ubiquitination|
|PcG protein complex|
|histone monoubiquitination|
|histone ubiquitination|
|protein monoubiquitination|
|regulation of gene expression, epigenetic|
|RNA polymerase II regulatory region sequence-specific DNA binding|
|histone modification|
|covalent chromatin modification|
|centrosome|
|DNA-binding transcription factor activity|
|protein ubiquitination|
|chromatin organization|
|protein modification by small protein conjugation|
|nucleolus|
|protein modification by small protein conjugation or removal|
|chromosome organization|
|positive regulation of transcription by RNA polymerase II|
|positive regulation of transcription, DNA-templated|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|positive regulation of RNA metabolic process|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp141|Nifurtimox 1μM R03 exp141]]|-2.05|
|[[:results:exp278|CVT-10216 0.1μM R06 exp278]]|-1.88|
|[[:results:exp376|Losmapimod 1μM R07 exp376]]|-1.77|
|[[:results:exp222|Betulinic acid 10 to 15μM on day4 R05 exp222]]|-1.74|
|[[:results:exp537|WNT3A 44ng/ml R08 exp537]]|1.85|
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: 1/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|1/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 16901
* **Expression level (log2 read counts)**: 5.67
{{:chemogenomics:nalm6 dist.png?nolink |}}